Inclusion Criteria:

          1. Males > 18 years who have gone through external or internal, high dose rate (brachy)
             radiation therapy for localized prostate cancer with histopathologically verified
             local recurrence.

          2. Prostate volume less than 50 cm3 defined by transrectal ultrasound

          3. Subject not eligible for surgery or curative radiotherapy

          4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          5. Expected survival ≥ 8 months

          6. Sufficient bone marrow reserve as indicated by; granulocyte count ≥ 1500/mm3, platelet
             count ≥ 100,000/mm3

          7. Adequate renal function as defined by creatinine ≤ 1.5 mg /dl

          8. Adequate hepatic function, based on a total bilirubin ≤ 1.5 mg/dl, serum
             glutamate-oxaloacetate transaminase (SGOT) ≤ 3 times the upper limit of normal, and
             alanine transaminase (ALT) ≤ 3 times the upper limit of normal

          9. Signed Informed Consent

        Exclusion Criteria:

          1. Patients with locally advanced (AJCC 7th edition T3/T4) or metastatic disease

          2. Patients who have been treated with seed implantation brachytherapy

          3. Gleason score ≥ 8 at initial diagnosis

          4. Less than 1 week since surgery (excluding minimal procedures, e.g. vascular access
             device insertion)

          5. Concomitant infection

          6. Subjects with other severe concurrent disease that in the judgement of the
             investigator would make the subject inappropriate for entry into this study

          7. Mental incapacity or psychiatric illness that would interfere with the subject's
             ability to understand and give informed consent or to complete follow-up visits
             according to the judgement of the investigator

          8. Contraindication for photosensitizer

          9. Porphyria or other diseases exacerbated by light

         10. Known hypersensitivity to verteporfin for injection (VFI) or to any of the excipients

         11. Known allergies to porphyrins

         12. Tumours known to be eroding into a major blood vessel in or adjacent to the
             illumination site

         13. On-going therapy with a photosensitizing agent

         14. Enrolment in another therapeutic clinical study within 3 months prior to randomization
             and throughout the study.

         15. Subjects with a history of CTCAE v4 grade 3 or greater or persistent (>1 separate
             episode or symptoms lasting more than 3 months after initiation of medical
             intervention) grade 2 proctitis attributed to radiation.